ADC Therapeutics S.A.

ADC Therapeutics S.A. is a biotechnology company engaged in developing and commercializing antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. The primary goal of ADC Therapeutics is to address major unmet medical needs by harnessing the potency of targeted drug delivery. By combining the targeting capability of monoclonal antibodies with the cancer-killing effects of potent cytotoxic drugs, the company's ADCs aim to selectively attack cancer cells while minimizing damage to healthy tissues. ADC Therapeutics targets a range of malignancies, including non-Hodgkin lymphoma and other aggressive blood cancers, with a robust pipeline of therapeutics in various stages of clinical trials. Headquartered in Switzerland, the company plays a significant role in the biopharmaceutical industry, collaborating with other research entities and leveraging cutting-edge technology to advance cancer treatment. Its scientific innovation and potential breakthrough therapies contribute substantially to the evolving landscape of oncology medicine.